Clinical Trial Update: Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating arhalofenate for preventing flares and lowering serum uric acid in gout patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• Arhalofenate (arhalofenate)

Snippet

Sponsor: Gilead Sciences | Conditions: Gout | Phase 2 | Status: COMPLETED